Showing results (571-580 of 661) with videos related to
Sort By:
Pageof 67
The New England Journal of Medicine|October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12CMarwan G Fakih, Lisa Salvatore, Taito Esaki, et al.Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.British Journal of Cancer|June 22, 2018
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trialAlison C Backen, Andre Lopes, Harpreet Wasan, et al.Plos Genetics|June 23, 2022
Exome sequencing in multiplex families with left-sided cardiac defects has high yield for disease gene discoveryDavid M Gordon, David Cunningham, Gloria Zender, et al.The Lancet. Oncology|July 17, 2015
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trialJuan W Valle, Harpreet Wasan, Andre Lopes, et al.The New England Journal of Medicine|July 11, 2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerDavid Cunningham, William H Allum, Sally P Stenning, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyNiall C Tebbutt, Kate Wilson, Val J Gebski, et al.Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.International Journal of Cancer|September 30, 2016
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trialFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.Future Oncology (London, England)|December 10, 2025
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphomaNathalie A Johnson, Pier Luigi Zinzani, Eva Domingo-Domenech, et al.Pageof 67